Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials

References

• Fulster S , Tacke M , Sandek A , et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013;34(7):512–519.
   PubMed Web of Science ®Google Scholar
• Watanabe H , Enoki Y , Maruyama T. Sarcopenia in chronic kidney disease: factors, mechanisms, and therapeutic interventions. Biol Pharm Bull. 2019;42(9):1437–1445.
   PubMed Web of Science ®Google Scholar
• Ryan AM , Prado CM , Sullivan ES , et al. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition. 2019;6768:110539.
   Google Scholar
• Ebner N , Anker SD , von Haehling S. Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference. J Cachexia Sarcopenia Muscle. 2019;10(1):218‐225. DOI: 10.1002/jcsm.v10.1
   Google Scholar
• Argilés JM , Busquets S , Stemmler B , et al. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol. 2015;22:100–106.
   PubMed Web of Science ®Google Scholar
• Kuki A , Tanaka K , Kushiyama A , et al. Association of gait speed and grip strength with risk of cardiovascular events in patients on haemodialysis: a prospective study. BMC Nephrol. 2019;20(1):196.
   PubMed Web of Science ®Google Scholar
• Liu P , Hao Q , Hai S , et al. Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: A systematic review and meta-analysis. Maturitas. 2017;103:16–22.
   PubMed Web of Science ®Google Scholar
• Basaria S , Wahlstrom JT , Dobs AS . Clinical review 138: anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab. 2001;86(11):5108–5117.
   PubMed Web of Science ®Google Scholar
• Travison TG , Basaria S , Storer TW , et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2011;66(10):1090–1099.
   PubMed Web of Science ®Google Scholar
• Caminiti G , Volterrani M , Iellamo F , et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54(10):919–927.
   PubMed Web of Science ®Google Scholar
• Holmäng S , Mårin P , Lindstedt G , et al. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate. 1993;23(2):99–106.
   PubMed Web of Science ®Google Scholar
• Urman B , Pride SM , Yuen BH . Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol. 1991;77(4):595–598.
   PubMed Web of Science ®Google Scholar
• Basaria S , Harman SM , Travison TG , et al., Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314(6):570–581.
   PubMed Web of Science ®Google Scholar
• Narayanan R , Coss CC , Dalton JT . Development of selective androgen receptor modulators (SARMs). Mol Cell Endocrinol. 2018;465:134–142.
   PubMed Web of Science ®Google Scholar
• Smith CL , O’Malley BW . Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev. 2004;25(1):45–71.
   PubMed Web of Science ®Google Scholar
• Komrakova M , Furtwängler J , Hoffmann DB , et al. The selective androgen receptor modulator ostarine improves bone healing in ovariectomized rats. Calcif Tissue Int. 2020;106(2):147–157.
   PubMed Web of Science ®Google Scholar
• Aikawa K , Miyawaki T , Hitaka T , et al. Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part I. Bioorg Med Chem. 2015;23(10):2568–2578.
   PubMed Web of Science ®Google Scholar
• Piatnitski Chekler EL , Unwalla R , Khan TA , et al. 1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulators. J Med Chem. 2014;57(6):2462–2471.
   PubMed Web of Science ®Google Scholar
• Jones A , Hwang DJ , Narayanan R , et al. Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology. 2010;151(8):3706–3719.
   PubMed Web of Science ®Google Scholar
• Allan G , Sbriscia T , Linton O , et al. A selective androgen receptor modulator with minimal prostate hypertrophic activity restores lean body mass in aged orchidectomized male rats. J Steroid Biochem Mol Biol. 2008;110(35):207–213.
   PubMedGoogle Scholar
• Basaria S , Collins L , Dillon EL , et al., The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87–95.
   PubMed Web of Science ®Google Scholar
• Neil D , Clark RV , Magee M , et al., GSK2881078, a SARM, produces dose-dependent increases in lean mass in healthy older men and women. J Clin Endocrinol Metab. 2018;103(9):3215–3224.
   PubMed Web of Science ®Google Scholar
• Dalton JT , Barnette KG , Bohl CE , et al., The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2(3):153–161.
   PubMed Web of Science ®Google Scholar
• Papanicolaou DA , Ather SN , Zhu H , et al., A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. J Nutr Health Aging. 2013;17(6):533–543.
   PubMed Web of Science ®Google Scholar
• Dobs AS , Boccia RV , Croot CC , et al., Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–345.
   PubMed Web of Science ®Google Scholar
• Gao W , Bohl CE , Dalton JT . Chemistry and structural biology of androgen receptor. Chem Rev. 2005;105(9):3352–3370.
   PubMed Web of Science ®Google Scholar
• Negro-Vilar A . Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab. 1999;84(10):3459–3462.
   PubMed Web of Science ®Google Scholar
• Azhagiya Singam ER , Tachachartvanich P , La Merrill MA , et al. Structural dynamics of agonist and antagonist binding to the androgen receptor. J Phys Chem B. 2019;123(36):7657–7666.
   PubMed Web of Science ®Google Scholar
• Heemers HV , Tindall DJ . Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007;28(7):778–808.
   Web of Science ®Google Scholar
• Dalton JT , Mukherjee A , Zhu Z , et al. Discovery of nonsteroidal androgens. Biochem Biophys Res Commun. 1998;244(1):1–4.
   PubMed Web of Science ®Google Scholar
• Thevis M , Volmer DA . Mass spectrometric studies on selective androgen receptor modulators (SARMs) using electron ionization and electrospray ionization/collision-induced dissociation. Eur J Mass Spectrom (Chichester). 2018;24(1):145–156.
   PubMed Web of Science ®Google Scholar
• Ostrowski J , Kuhns JE , Lupisella JA , et al. Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology. 2007;148(1):4–12.
   PubMed Web of Science ®Google Scholar
• Ebner N , von Haehling S. Silver linings on the horizon: highlights from the 10th Cachexia Conference. J Cachexia Sarcopenia Muscle. 2018;9(1):176‐182. doi:10.1002/jcsm.v9.1
   Google Scholar
• GTx I . GTx announced new data demonstrating enobosarm’s potential to treat stress urinary incontinence at SUFU 2018. Mar 5 2018. [cited 2020 May 2]. Available from: https://www.biospace.com/article/releases/gtx-announced-new-data-demonstrating-enobosarm-s-potential-to-treat-stress-urinary-incontinence-at-sufu-2018/.
   Google Scholar
• Sheffield M . Steiner resigns from GTx. April 4, 2014. [cited 2020 May 2]. Available from: https://www.bizjournals.com/memphis/news/2014/04/04/steiner-resigns-from-gtx.html
   Google Scholar
• Coss CC , Jones A , Dalton JT . Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. Invest New Drugs. 2016;34(4):458–467.
   Web of Science ®Google Scholar
• Dubois V , Simitsidellis I , Laurent MR , et al. Enobosarm (GTx-024) modulates adult skeletal muscle mass independently of the androgen receptor in the satellite cell lineage. Endocrinology. 2015;156(12):4522–4533.
   PubMed Web of Science ®Google Scholar
• Morimoto M , Aikawa K , Hara T , et al. Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models. Oncol Lett. 2017;14(6):8066–8071.
   Web of Science ®Google Scholar
• Kim J , Wang R , Veverka KA , et al. Absorption, distribution, metabolism and excretion of the novel SARM GTx-024 [(S)-N(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide] in rats. Xenobiotica. 2013;43(11):993–1009.
   PubMed Web of Science ®Google Scholar
• Crawford J , Prado CM , Johnston MA , et al. Study design and rationale for the Phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials). Curr Oncol Rep. 2016;18(6):37.
   Web of Science ®Google Scholar
• Crawford J , Johnston M , Taylor R , et al. Enobosarm and lean body mass in patients with non-small cell lung cancer. J clin oncol. 2014 [cited 2020 Jan 10 ];32(15_suppl):9618. Available from: https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.9618
   Google Scholar
• Thevis M , Schänzer W . Detection of SARMs in doping control analysis. Mol Cell Endocrinol. 2018;464:34–45.
   PubMed Web of Science ®Google Scholar
• Thevis M , Geyer H , Thomas A , et al. Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet. Drug Test Anal. 2011;3(5):331–336.
   PubMed Web of Science ®Google Scholar
• Clark RV , Walker AC , Andrews S , et al. Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women. Br J Clin Pharmacol. 2017;83(10):2179–2194.
   PubMed Web of Science ®Google Scholar
• Nique F , Hebbe S , Triballeau N , et al. Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator. J Med Chem. 2012;55(19):8236–8247.
   PubMed Web of Science ®Google Scholar
• Blanqué R , Lepescheux L , Auberval M , et al. Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization. BMC Musculoskelet Disord. 2014;15(1):291.
   PubMedGoogle Scholar
• Cozzoli A , Capogrosso RF , Sblendorio VT , et al. GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy. Pharmacol Res. 2013;72:9–24.
   PubMed Web of Science ®Google Scholar
• Akashi T DT-200: muscle Builder. [cited 2020 Jan 10 ]. Available at: https://akashirx.com/pipeline
   Google Scholar
• Hamann LG , Mani NS , Davis RL , et al. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-Ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g] quinoline (LG121071). J Med Chem. 1999;42(2):210–212.
   PubMed Web of Science ®Google Scholar
• Viking T . Viking signs broad licensing deal with ligand pharmaceuticals for rights to five novel therapeutic programs. May 22, 2014. [cited 2020 May 2]. Available from: https://www.vikingtherapeutics.com/2014/05/22/viking-signs-broad-licensing-deal-with-ligand-pharmaceuticals-for-rights-to-five-novel-therapeutic-programs/
   Google Scholar
• Vajda EG , López FJ , Rix P , et al. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. J Pharmacol Exp Ther. 2009;328(2):663–670.
   Web of Science ®Google Scholar
• Vajda EG , Hogue A , Griffiths KN , et al. Combination treatment with a selective androgen receptor modulator q(SARM) and a bisphosphonate has additive effects in osteopenic female rats. J Bone Miner Res. 2009;24(2):231–240.
   PubMed Web of Science ®Google Scholar
• Miner JN , Chang W , Chapman MS , et al. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007;148(1):363–373.
   PubMed Web of Science ®Google Scholar
• Reiter M , Tichopad A , Riedmaier I , et al. Monitoring gene expression in muscle tissue of macaca fascicularis under the influence of testosterone and SARM. Horm Mol Biol Clin Investig. 2010;1(2):73–79.
   Google Scholar
• Schmidt A , Kimmel DB , Bai C , et al. Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem. 2010;285(22):17054–17064.
   PubMed Web of Science ®Google Scholar
• Chisamore MJ , Gentile MA , Dillon GM , et al. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice. J Steroid Biochem Mol Biol. 2016;163:88–97.
   PubMed Web of Science ®Google Scholar
• Miller CP , Shomali M , Lyttle CR , et al. Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140. ACS Med Chem Lett. 2011;2(2):124–129.
   PubMed Web of Science ®Google Scholar
• Yu Z , He S , Wang D , et al. Selective androgen receptor modulator RAD140 inhibits the growth of androgen/estrogen receptor-positive breast cancer models with a distinct mechanism of action. Clin Cancer Res. 2017;23(24):7608–7620.
   PubMed Web of Science ®Google Scholar
• Jayaraman A , Christensen A , Moser VA , et al. Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats. Endocrinology. 2014;155(4):1398–1406.
   PubMed Web of Science ®Google Scholar
• Allan GF , Tannenbaum P , Sbriscia T , et al. A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats. Endocrine. 2007;32(1):41–51.
   PubMed Web of Science ®Google Scholar
• Wu D , Wu Z , Yang J , et al. Pharmacokinetics and metabolism of a selective androgen receptor modulator in rats: implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study. Drug Metab Dispos. 2006;34(3):483–494.
   PubMed Web of Science ®Google Scholar
• Gao W , Reiser PJ , Coss CC , et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology. 2005;146(11):4887–4897.
   PubMed Web of Science ®Google Scholar
• Hanada K , Furuya K , Yamamoto N , et al. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull. 2003;26(11):1563–1569.
   PubMed Web of Science ®Google Scholar
• Bhattacharya I , Tarabar S , Liang Y , et al. Safety, pharmacokinetic, and pharmacodynamic evaluation after single and multiple ascending doses of a novel selective androgen receptor modulator in healthy subjects. Clin Ther. 2016;38(6):1401–1416.
   PubMed Web of Science ®Google Scholar
• Krishnan V , Patel NJ , Mackrell JG , et al. Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients. Andrology. 2018;6(3):455–464.
   PubMed Web of Science ®Google Scholar
• Zierau O , Kolodziejczyk A , Vollmer G , et al. Comparison of the three SARMs RAD-140, GLPG0492 and GSK-2881078 in two different in vitro bioassays, and in an in silico androgen receptor binding assay. J Steroid Biochem Mol Biol. 2019;189:81–86.
   PubMed Web of Science ®Google Scholar
• Garber K . No longer going to waste. Nat Biotechnol. 2016;34(5):458–461.
   PubMed Web of Science ®Google Scholar
• Solheim TS , Laird BJA , Balstad TR , et al. Cancer cachexia: rationale for the MENAC (Multimodal-exercise, nutrition and anti-inflammatory medication for Cachexia) trial. BMJ Support Palliat Care. 2018;8(3):258–265.
   PubMed Web of Science ®Google Scholar
• Temel JS , Abernethy AP , Currow DC , et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519–531.
   PubMed Web of Science ®Google Scholar
• Currow D , Temel JS , Abernethy A , et al. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol. 2017;28(8):1949–1956.
   PubMed Web of Science ®Google Scholar
• Stewart Coats AJ , Ho GF , Prabhash K , et al. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial). J Cachexia Sarcopenia Muscle. 2016;7(3):355–365.
   PubMed Web of Science ®Google Scholar
• Bauer J , Morley JE , Schols AMWJ , et al. Sarcopenia: a time for action. An SCWD position paper. J Cachexia Sarcopenia Muscle. 2019;10(5):956–961.
   PubMed Web of Science ®Google Scholar